To substantiate the CD8+ T cell activity activated by DC/tumor fusion vaccine+LPS-Nb36 treatment in damaged tumor cells in vivo, we established HepG2, A549, and MGC-803 subcutaneous xenograft mice models. Here, CD8A is linked to neoplasm.